Rubius Therapeutics, Inc. Quarterly Debt-to-equity in % from Q1 2019 to Q4 2022

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Rubius Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q1 2019 to Q4 2022.
Rubius Therapeutics, Inc. Debt-to-equity for the quarter ending December 31, 2022 was 145 %, a 161% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q4 2022	145	+89.3	+161%	Dec 31, 2022
Q3 2022	121	+63.7	+111%	Sep 30, 2022
Q2 2022	85.6	+24.6	+40.3%	Jun 30, 2022
Q1 2022	67.4	+1.21	+1.83%	Mar 31, 2022
Q4 2021	55.5	-14.4	-20.5%	Dec 31, 2021
Q3 2021	57.4	-0.26	-0.45%	Sep 30, 2021
Q2 2021	61	+12.3	+25.3%	Jun 30, 2021
Q1 2021	66.2	+27.2	+69.6%	Mar 31, 2021
Q4 2020	69.9	+38.3	+121%	Dec 31, 2020
Q3 2020	57.7	+31.2	+118%	Sep 30, 2020
Q2 2020	48.7	+29.5	+153%	Jun 30, 2020
Q1 2020	39.1	+17.8	+83.4%	Mar 31, 2020
Q4 2019	31.6			Dec 31, 2019
Q3 2019	26.5			Sep 30, 2019
Q2 2019	19.2			Jun 30, 2019
Q1 2019	21.3			Mar 31, 2019

* An asterisk sign (*) next to the value indicates that the value is likely invalid.